Serum circulating miRNA‐342‐3p as a potential diagnostic biomarker in parathyroid carcinomas: A pilot study

Abstract Objective To compare the serum miRNA expression profiles between patients with benign and malignant parathyroid tumours. Background Despite recent advances in molecular biology, a histological tissue biopsy is still the method of choice used to diagnose most cancers. The preoperative cytolo...

Full description

Bibliographic Details
Main Authors: Julia Krupinova, Natalya Mokrysheva, Vasiliy Petrov, Ekaterina Pigarova, Anna Eremkina, Ekaterina Dobreva, Alina Ajnetdinova, Galina Melnichenko, Anatoly Tiulpakov
Format: Article
Language:English
Published: Wiley 2021-10-01
Series:Endocrinology, Diabetes & Metabolism
Subjects:
Online Access:https://doi.org/10.1002/edm2.284
Description
Summary:Abstract Objective To compare the serum miRNA expression profiles between patients with benign and malignant parathyroid tumours. Background Despite recent advances in molecular biology, a histological tissue biopsy is still the method of choice used to diagnose most cancers. The preoperative cytology is not an applicable method for diagnosis of parathyroid cancer (PC); therefore, huge interest exists in terms of finding alternative methodologies to seek specific cancer biomarkers. Design A retrospective cross‐sectional study. Patients and Methods Serum samples of patients with PC (n = 13) and parathyroid adenoma (PA) (n = 11), age (p = .999) and sex (p = .999) were matched and examined via the simultaneous comparative expression analysis of 754 microRNAs (miRNAs). The «TaqMan OpenArray Human MicroRNA Panel» (Applied Biosystems) was used to conduct real‐time PCRs using the «QuantStudio 12К Flex» station (Life Technologies). Results According to the results of a pilot study, significant changes in expression levels between the PC group and the PA group (control) (p < .05) were observed for 17 miRNAs. Among them, the downregulation of miRNA‐342‐3p met the Benjamini‐Hochberg adjustment criteria for multiple comparisons (p = .02). Conclusions Serum miRNA‐342‐3p could be a promising biomarker for PC to improve diagnosis and prognosis.
ISSN:2398-9238